This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell engagers, and antibody-drug conjugates. Faculty discuss emerging clinical evidence for investigational approaches across both extensive-stage and limited-stage disease settings. Emphasis is placed on how disease stage, prior treatment exposure, mechanism of action, and evolving trial data can inform treatment selection, clinical trial referral, and future integration of antigen-directed therapies into SCLC care.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
CME included with membership
| Free Registration | Free |
| Tufts-Affiliated HCP - Early Bird (by 10/5/26) | $75 |
| Tufts-Affiliated HCP - Standard | $175 |
| Trainees & Allied Health - Early Bird (by 10/5/26) | $75 |
| Trainees & Allied Health - Standard | $175 |
| Physicians - Early Bird (by 10/5/26) | $150 |
+3 more tiers
Collected from the provider’s public pages · source
Specialties served/covered
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- General & Adult Psychiatry
- General Pediatrics
- Gynecologic Oncology
- Head & Neck Surgery
- Hematology
- Maternal-Fetal Medicine
- Medical Genetics & Genomics
- Medical Oncology
- Mood & Anxiety Disorders
- Nephrology
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Obstetrics & Gynecology
- Ophthalmology
- Pediatric Neurology
- Psychopharmacology
- Psychotic Disorders
- Pulmonary Disease
- Radiation Oncology
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Transplant Hepatology
- Urological Oncology
- Vascular Neurology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 0.5 credits
- Commercial Support
-
ReleasedJul 27, 2026
-
Last day to claim creditJul 28, 2027 10 months left
-
Learner’s Digest International (TM) Chimeric Antigen Receptor T-Cell Therapy for Leptomeningeal Disease from Primary Brain Tumors
-
American College of Emergency Physicians Annals February 2026: Major Adverse Events with Chimeric Antigen Receptor T-Cell Therapy: Presentation, Diagnosis, and Resuscitation
-
Emerging Infectious Diseases +1 Blastomyces Antigen Testing in Urine for Active Case Identification During a Blastomycosis Outbreak
-
Global Learning Collaborative Spotlight on B7-H3 ES-SCLC: Applying ADC Evidence in Real-World Practice
-
Global Learning Collaborative The Frontline Imperative: Integrating Anti-CD38 Based Regimens Into Multiple Myeloma Care in Community Practice
-
Global Learning Collaborative Redefining First-Line Therapy of Metastatic TNBC: Integrating TROP2-Directed ADCs Into Modern Treatment Strategy
